A new combination therapy using 177Lu PSMA-617 and idronoxil (NOX66) is effective for treating patients with prostate cancer, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting in Anaheim, California.
A new combination therapy using 177Lu PSMA-617 and idronoxil (NOX66) is effective for treating patients with prostate cancer, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting in Anaheim, California.